In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC

about

Plasma microRNA alterations between EGFR-activating mutational NSCLC patients with and without primary resistance to TKI.Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines.

P2860

Q47098762-A9FE89DE-C80D-4BB7-AD42-494B4A5A310D Q48158087-6B928033-7180-4868-B694-134285EDA944

P2860

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC

Item

http://www.wikidata.org/entity/Q37694812

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

In pursuit of synergy: An inve ...... d inhibition strategy in NSCLC

@en

In pursuit of synergy: An inve ...... inhibition strategy in NSCLC.

@nl

type

Item

label

In pursuit of synergy: An inve ...... d inhibition strategy in NSCLC

@en

In pursuit of synergy: An inve ...... inhibition strategy in NSCLC.

@nl

prefLabel

In pursuit of synergy: An inve ...... d inhibition strategy in NSCLC

@en

In pursuit of synergy: An inve ...... inhibition strategy in NSCLC.

@nl

P1476

In pursuit of synergy: An inve ...... d inhibition strategy in NSCLC

@en

P2093

Kenneth O'Byrne

http://www.w3.org/2001/XMLSchema#string

Niall McVeigh

http://www.w3.org/2001/XMLSchema#string

Niamh Leonard

http://www.w3.org/2001/XMLSchema#string

Ronan Ryan

http://www.w3.org/2001/XMLSchema#string

Sinead Cuffe

http://www.w3.org/2001/XMLSchema#string

Siobhan Nicholson

http://www.w3.org/2001/XMLSchema#string

Vincent Young

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

New driver mutations in non-small-cell lung cancer.

Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.

Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer

The Global Burden of Cancer 2013

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.

P304

79526-79543

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.12755

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27765909

http://www.w3.org/2001/XMLSchema#string

P932

5346733

http://www.w3.org/2001/XMLSchema#string

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC

about

P2860

P2860

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932